^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    CD137 agonist

    Related drugs:
    5d
    Tri-specific Humabody CB307 Targeting CD137, Prostate-specific Membrane Antigen, and Human Serum Albumin Whole-body Biodistribution Measured with 89Zr-CB307 PET. (PubMed, Mol Cancer Ther)
    Tumor biopsies confirmed radioactivity. 89Zr-CB307 selectively accumulated in PSMA-positive tumor lesions without specific uptake in PSMA-positive-normal or lymphoid tissues in patients with mCRPC.
    Journal • IO biomarker
    |
    FOLH1 (Folate hydrolase 1) • TNFRSF9 (TNF Receptor Superfamily Member 9)
    |
    FOLH1 expression • FOLH1 positive
    |
    CB307
    9d
    IgG2a-formatted 4-1BB agonism combined with S100A9 inhibition enhances T cell activation and tumor control in a preclinical model of multiple myeloma. (PubMed, J Exp Clin Cancer Res)
    These findings establish the isotype-specific efficacy of 4-1BB agonists and support 4-1BB stimulation combined with TQ as a promising strategy to enhance durable immunotherapeutic responses in MM.
    Preclinical • Journal • IO biomarker
    |
    IFNG (Interferon, gamma) • NCAM1 (Neural cell adhesion molecule 1) • TNFRSF9 (TNF Receptor Superfamily Member 9) • S100A9 (S100 Calcium Binding Protein A9) • GZMB (Granzyme B) • CD86 (CD86 Molecule)
    |
    tasquinimod (ABR-215050) • urelumab (BMS-663513)
    13d
    GCT1046-04: Safety and Efficacy Study of GEN1046 as a Single Agent or in Combination With Pembrolizumab for Treatment of Recurrent (Non-small Cell) Lung Cancer (clinicaltrials.gov)
    P2, N=125, Active, not recruiting, Genmab | Trial completion date: May 2027 --> Aug 2026
    Trial completion date • Checkpoint inhibition
    |
    PD-L1 expression
    |
    Keytruda (pembrolizumab) • acasunlimab (GEN1046)
    14d
    CAB-201-002: RESET-Myositis: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Idiopathic Inflammatory Myopathy (2025-521145-24-01)
    P1/2, N=6, Not yet recruiting, Cabaletta Bio Inc.
    New P1/2 trial
    |
    cyclophosphamide
    19d
    Quantitative Investigation of ATP Switch Concept of STA551 Through Combined In Vivo Tissue Distribution Studies and Physiologically Based Pharmacokinetic Modeling. (PubMed, AAPS J)
    In conclusion, this combination approach successfully demonstrated the ATP switch concept of STA551 in vivo. These findings will help guide clinical trials for STA551 and the development of future switch antibodies.
    PK/PD data • Preclinical • Journal
    |
    TNFRSF9 (TNF Receptor Superfamily Member 9)
    |
    STA551
    20d
    A Phase II Clinical Trial of LBL-024 Combination Drug in Patients With Advanced Solid Tumour[Substudy 04] (clinicaltrials.gov)
    P2, N=110, Recruiting, Nanjing Leads Biolabs Co.,Ltd | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Tevimbra (tislelizumab-jsgr) • capecitabine • oxaliplatin
    22d
    Cibisatamab and FAP-4-1BBL in microsatellite-stable colorectal cancer: a phase 1b trial. (PubMed, Nat Med)
    Patients received cibisatamab with escalating doses of FAP-4-1BBL weekly or every 3 weeks after obinutuzumab pretreatment to mitigate anti-drug antibody formation. These findings demonstrate the feasibility of combining tumor antigen-directed T cell engagement with localized co-stimulation, with evidence of immune activation and preliminary antitumor activity supporting further clinical development. ClinicalTrials.gov identifier: NCT04826003 .
    P1 data • Journal • IO biomarker
    |
    CD8 (cluster of differentiation 8) • IFNG (Interferon, gamma) • CEACAM5 (CEA Cell Adhesion Molecule 5) • IL2RA (Interleukin 2 receptor, alpha) • TNFRSF9 (TNF Receptor Superfamily Member 9)
    |
    Gazyva (obinutuzumab) • RG7827 • cibisatamab (RG7802)
    27d
    Precision modeling of tumor antigen-specific T-cell responses in humanized mice for preclinical assessment of cancer immunotherapies. (PubMed, J Immunother Cancer)
    This adaptable and physiologically relevant model provides a platform to dissect the complex interplay between human tumors, immune cells, and immunotherapies and has the potential to significantly improve the translation of preclinical findings to the clinic.
    Preclinical • Journal
    |
    PD-1 (Programmed cell death 1) • CD40 (CD40 Molecule)
    |
    RG7827
    28d
    BGB-B2033-101: A Phase 1 Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Selected Advanced or Metastatic Solid Tumors (2025-524136-19-00)
    P1, N=56, Not yet recruiting, BeOne Medicines AG
    New P1 trial
    |
    Avastin (bevacizumab) • Tevimbra (tislelizumab-jsgr)
    1m
    Neoadjuvant Nivolumab With and Without Urelumab in Cisplatin-Ineligible or Chemotherapy-refusing Patients With Muscle-Invasive Urothelial Carcinoma of the Bladder (clinicaltrials.gov)
    P2, N=15, Active, not recruiting, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Trial completion date: Dec 2026 --> Dec 2027 | Trial primary completion date: Jul 2026 --> Jul 2027
    Trial completion date • Trial primary completion date • IO biomarker
    |
    PD-L1 (Programmed death ligand 1)
    |
    Opdivo (nivolumab) • urelumab (BMS-663513)
    1m
    GEN1046 Safety Trial in Patients With Malignant Solid Tumors (clinicaltrials.gov)
    P1/2, N=429, Active, not recruiting, Genmab | Trial completion date: Feb 2026 --> Aug 2026
    Trial completion date • First-in-human
    |
    Keytruda (pembrolizumab) • docetaxel • acasunlimab (GEN1046)
    2ms
    A Clinical Trial of LBL-024 Combined With Etoposide and Platinum in Patients With Advanced Neuroendocrine Carcinoma (clinicaltrials.gov)
    P1/2, N=178, Recruiting, Nanjing Leads Biolabs Co.,Ltd | Trial completion date: Jul 2027 --> Mar 2027
    Trial completion date
    |
    cisplatin • Tecentriq (atezolizumab) • carboplatin • etoposide IV